SLITRK6 explained

SLIT and NTRK-like protein 6 is a protein that in humans is encoded by the SLITRK6 gene.[1]

Function

Members of the SLITRK family, such as SLITRK6, are integral membrane proteins with 2 N-terminal leucine-rich repeat (LRR) domains similar to those of SLIT proteins (see SLIT1). Most SLITRKs, including SLITRK6, also have C-terminal regions that share homology with neurotrophin receptors (see NTRK1). SLITRKs are expressed predominantly in neural tissues and have neurite-modulating activity.[1] [2]

Clinical significance

Mutations in SLITRK6 cause high myopia and deafness in humans and mice.[3]

As a drug target

The protein is the target for the antibody-drug conjugate ASG-15ME which is in phase 1 clinical trials for urothelial cancer.[4]

Further reading

Notes and References

  1. Aruga J, Yokota N, Mikoshiba K . Human SLITRK family genes: genomic organization and expression profiling in normal brain and brain tumor tissue . Gene . 315 . 87–94 . Oct 2003 . 14557068 . 10.1016/S0378-1119(03)00715-7 .
  2. Web site: Entrez Gene: SLITRK6 SLIT and NTRK-like family, member 6.
  3. Tekin M, Chioza BA, Matsumoto Y, Diaz-Horta O, Cross HE, Duman D, Kokotas H, Moore-Barton HL, Sakoori K, Ota M, Odaka YS, Foster J, Cengiz FB, Tokgoz-Yilmaz S, Tekeli O, Grigoriadou M, Petersen MB, Sreekantan-Nair A, Gurtz K, Xia XJ, Pandya A, Patton MA, Young JI, Aruga J, Crosby AH . SLITRK6 mutations cause myopia and deafness in humans and mice . J. Clin. Invest. . 123 . 5 . 2094–102 . 2013 . 23543054 . 3635725 . 10.1172/JCI65853 .
  4. Web site: Interim Analysis of a Phase 1 Dose Escalation Trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an Antibody-Drug Conjugate (ADC) in Patients with Metastatic Urothelial Cancer . Poster Abstract #788P, European Society for Medical Oncology (ESMO) Congress, Copenhagen . October 2016 . Seattle Genetics and Agensys, an Affiliate of Astellas .